CN113577111A - Liquid drop for preventing virus infection of mammals and treating intestinal diarrhea - Google Patents
Liquid drop for preventing virus infection of mammals and treating intestinal diarrhea Download PDFInfo
- Publication number
- CN113577111A CN113577111A CN202110982332.4A CN202110982332A CN113577111A CN 113577111 A CN113577111 A CN 113577111A CN 202110982332 A CN202110982332 A CN 202110982332A CN 113577111 A CN113577111 A CN 113577111A
- Authority
- CN
- China
- Prior art keywords
- diarrhea
- mammals
- virus infection
- liquid drop
- intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a liquid drop for preventing virus infection of mammals and treating intestinal diarrhea, which is prepared from the following raw materials in volume ratio: 1-5% of bifidobacterium lactis and 95-99% of medium-chain triglyceride. The invention can effectively prevent virus infection of mammals and treat intestinal diarrhea.
Description
Technical Field
The invention relates to the technical field of probiotics, in particular to a liquid drop for preventing virus infection of mammals and treating intestinal diarrhea.
Background
In mammalian species, immunity to pathogens is transferred from the mother to the offspring by maternal antibodies provided by the placenta or colostrum. The mother can only transfer those antibodies that are produced by the body due to natural exposure or vaccination. However, maternal antibody transfer levels are affected by recent exposure to specific pathogens. If the maternal colostrum contains insufficient amounts of antibodies against certain pathogens, the neonate will have insufficient immunity against these diseases.
Members of the canine and feline families share many features in common with humans and bovines. In particular, they utilize maternal passive immunization to protect newborns, are susceptible to infectious diarrhea and other intestinal diseases and lack an effective treatment for common diarrhea infections.
Diarrhea is commonly called as diarrhea, and means that the frequency of defecation obviously exceeds the frequency of daily habit, the feces is thin, the moisture is increased, the daily defecation amount exceeds 200g, or the diarrhea contains undigested food, purulent blood and mucus. Diarrhea is clinically accompanied by symptoms such as defecation urgency, anal discomfort, incontinence and the like. Usually, infection with pathogens such as bacteria, viruses or parasites is the leading cause of diarrhea, also known as infectious diarrhea or gastroenteritis, and the occurrence and spread of infectious diarrhea is considered to be a result of poor hygiene.
Currently, the most common method for treating the travel diarrhea, namely the bacterial infectious diarrhea, is antibiotic treatment, but the use of the antibiotic can greatly destroy the balance of normal flora in intestinal tracts of patients, and fatal secondary infection is easy to occur.
Disclosure of Invention
The invention aims to provide a liquid drop for preventing the virus infection of mammals and treating the intestinal diarrhea, which can effectively prevent the virus infection of the mammals and treat the intestinal diarrhea.
In order to solve the technical problems, the invention adopts the following technical scheme:
the invention provides a liquid drop for preventing virus infection of mammals and treating intestinal diarrhea, which is characterized by being prepared from the following raw materials in volume ratio: 1-5% of bifidobacterium lactis and 95-99% of medium-chain triglyceride.
The invention also relates to a preparation method of the liquid drop for preventing the virus infection of the mammals and treating the intestinal diarrhea, which comprises the following steps:
step 1: preparing milk bifidobacterium and medium-chain triglyceride as raw materials in proportion;
step 2: mixing the two materials, stirring at 45 deg.C below 45 deg.C, suspending completely, and bottling.
The using method comprises the following steps: one to two drops per administration, corresponding to 0.5 ml.
The invention has the beneficial effects that: can effectively prevent virus infection of mammals and treat intestinal diarrhea.
The following further explains the beneficial effects of the present invention in combination with the efficacy of the main ingredients in the present invention:
bifidobacterium lactis: 1. treatment of chronic diarrhea and antibiotic-associated diarrhea: the Bifidobacterium has the effect of regulating intestinal flora. Clinical observation and research on chronic diarrhea patients by using bifidobacterium show that after the bifidobacterium is taken for two weeks, the patients have abnormal stool frequency and shape and disappear clinical symptoms, the total effective rate is 90.3 percent, and the relapse rate is low. Bifidobacteria formulations have been used by many domestic hospitals as the first choice for the treatment of chronic diarrhea. In addition, bifidobacteria can also treat antibiotic-associated diarrheal diseases caused by overuse of antibiotics. 380 cases of pseudomembranous enteritis are treated by adopting the bifidobacterium preparation, the clinical total cure rate has no obvious difference, but the clinical side effect and the recurrence rate are both obviously reduced. The bifidobacterium has good treatment effect on acute and chronic diarrhea of children; 2. effectively relieving constipation: the bifidobacterium can inhibit the growth of intestinal putrefying bacteria and the formation of toxic metabolites by adjusting intestinal flora and generating short-chain fatty acids such as acetic acid, lactic acid and the like, and stimulate the intestinal peristalsis, thereby reducing excessive water absorption and relieving constipation symptoms; 3. promoting the digestion of lactose by human body: milk contains rich nutrients. Lactose in milk is not broken down by lactase deficient persons who often develop gastrointestinal disturbances after drinking milk, resulting in gastrointestinal cramps, bloating or diarrhea, i.e. lactose intolerance. The fermented yogurt is prepared by fermenting milk with lactobacillus such as lactobacillus bulgaricus, streptococcus thermophilus and bifidobacterium, and can effectively relieve lactose intolerance.
Medium chain triglycerides: the medium chain triglyceride has functions of supplying body and storing energy, and has functions of fixing and protecting viscera.
Detailed Description
The technical solutions of the present invention will be described clearly and completely in the following embodiments of the present invention, and it should be understood that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A liquid drop for preventing virus infection of mammals and treating intestinal diarrhea is prepared from the following raw materials: 2% of bifidobacterium lactis and 98% of medium-chain triglyceride.
The preparation method of the liquid drop for preventing the virus infection of the mammals and treating the intestinal diarrhea comprises the following specific steps:
step 1: preparing milk bifidobacterium and medium-chain triglyceride as raw materials in proportion;
step 2: mixing the two raw materials, stirring for 45 min at 30 deg.C, suspending completely and uniformly, and bottling.
Example 2
A liquid drop for preventing virus infection of mammals and treating intestinal diarrhea is prepared from the following raw materials: bifidobacterium lactis 1% and medium chain triglyceride 99%.
The preparation method of the liquid drop for preventing the virus infection of the mammals and treating the intestinal diarrhea comprises the following specific steps:
step 1: preparing milk bifidobacterium and medium-chain triglyceride as raw materials in proportion;
step 2: mixing the two raw materials, stirring for 45 min at 40 deg.C, suspending completely and packaging.
Example 3
A liquid drop for preventing virus infection of mammals and treating intestinal diarrhea is prepared from the following raw materials: 4% of bifidobacterium lactis and 96% of medium-chain triglyceride.
The preparation method of the liquid drop for preventing the virus infection of the mammals and treating the intestinal diarrhea comprises the following specific steps:
step 1: preparing milk bifidobacterium and medium-chain triglyceride as raw materials in proportion;
step 2: mixing the two raw materials, stirring for 45 min at 32 deg.C, suspending completely and packaging.
Clinical trials applying the present invention:
the trial participants were 120 cases, wherein 60 cases of men and 60 cases of women were aged 10-55 years, and 120 cases were diarrhea patients, and 120 cases were divided into 3 groups, and the 3 groups were similar as much as possible, so that the patients were comparable.
The treatment method comprises the following steps: the administration is once a day and half a month later.
Diagnostic criteria
The method has the following advantages: the diarrhea condition is improved.
As a result: in example 1, 120 testers are effective, and the effective rate is 91.7%.
In example 2, 120 testers are effective, and the effective rate is 95.8%.
In example 3, 120 testers, 112 effective, and 93.3% effective rate.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.
Claims (1)
1. A liquid drop for preventing virus infection of mammals and treating intestinal diarrhea is characterized by being prepared from the following raw materials in volume ratio: 1-5% of bifidobacterium lactis and 95-99% of medium-chain triglyceride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110982332.4A CN113577111A (en) | 2021-08-25 | 2021-08-25 | Liquid drop for preventing virus infection of mammals and treating intestinal diarrhea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110982332.4A CN113577111A (en) | 2021-08-25 | 2021-08-25 | Liquid drop for preventing virus infection of mammals and treating intestinal diarrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113577111A true CN113577111A (en) | 2021-11-02 |
Family
ID=78239562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110982332.4A Pending CN113577111A (en) | 2021-08-25 | 2021-08-25 | Liquid drop for preventing virus infection of mammals and treating intestinal diarrhea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113577111A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110583937A (en) * | 2019-10-19 | 2019-12-20 | 上海英库商务咨询有限公司 | Bifidobacterium lactis beverage and preparation method thereof |
| CN110623271A (en) * | 2019-10-19 | 2019-12-31 | 上海英库商务咨询有限公司 | Bifidobacterium animalis beverage and its preparing process |
| CN111588738A (en) * | 2020-06-03 | 2020-08-28 | 金华银河生物科技有限公司 | Probiotic composition capable of relieving or treating travel diarrhea and application thereof |
-
2021
- 2021-08-25 CN CN202110982332.4A patent/CN113577111A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110583937A (en) * | 2019-10-19 | 2019-12-20 | 上海英库商务咨询有限公司 | Bifidobacterium lactis beverage and preparation method thereof |
| CN110623271A (en) * | 2019-10-19 | 2019-12-31 | 上海英库商务咨询有限公司 | Bifidobacterium animalis beverage and its preparing process |
| CN111588738A (en) * | 2020-06-03 | 2020-08-28 | 金华银河生物科技有限公司 | Probiotic composition capable of relieving or treating travel diarrhea and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 席德清: "乳脂及乳脂产品科学与技术", 中国物资出版社, pages: 160 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0923293B1 (en) | Treatment of diarrhea | |
| Kanamori et al. | Combination therapy with Bifidobacterium breve, Lactobacillus casei, and galactooligosaccharides dramatically improved the intestinal function in a girl with short bowel syndrome: a novel synbiotics therapy for intestinal failure | |
| US7125708B2 (en) | Composition comprising a Lactobacillus pentosus strain and uses thereof | |
| RU2468807C2 (en) | Baby food containing inactivated powder | |
| US6607905B1 (en) | Lactic ferment comprising a particular strain of lactobacillus acidophilus and use thereof | |
| JP2020516684A (en) | Methods of treating inflammation and inflammatory diseases | |
| DK2349295T3 (en) | A pharmaceutical composition comprising a combination of Streptococcus strains and Lactobacillus strains | |
| Vanderhoof | Probiotics in allergy management | |
| ITFI990051A1 (en) | PHARMACEUTICAL COMPOSITION BASED ON LACTIC FERMENTS AND NON-ABSORBABLE CARBOHYDRATIN CONTAINING A CALCIUM SALT AND AN ALUMINUM SALT | |
| EP1867238A1 (en) | Feeding stuff composition comprising proliferation promoting agent for bifidus bacteria and use of the same | |
| CN106822890A (en) | A kind of pharmaceutical composition for preventing and treating diarrhea of weaned piglets and its preparation method and application | |
| CN113577218A (en) | Inactivated probiotic traditional Chinese medicine composition for inhibiting helicobacter pylori and preparation method and application thereof | |
| US6358521B1 (en) | Fermented milk nutraceuticals | |
| CN113474447A (en) | Strains, compositions and methods of use | |
| CN109985069B (en) | Probiotic compositions and uses thereof | |
| CN113577111A (en) | Liquid drop for preventing virus infection of mammals and treating intestinal diarrhea | |
| CN110960561A (en) | Composite microbial inoculum for regulating balance of gynecological flora | |
| KR101086503B1 (en) | Pharmaceutical composition comprising lactobacillus and pharmaceutical composition of gold with culturing with lactobacillus for therapy against atopy dermatitis | |
| CN113559133A (en) | Liquid drop for preventing diarrhea, enhancing immunity, resisting infection and treating dermatitis | |
| Verma et al. | Therapeutic Effects of Dairy Products | |
| RU2071339C1 (en) | Agent for disbacteriosis treatment and prophylaxis | |
| RU2123345C1 (en) | Agent for disbacteriosis treatment | |
| Agüero et al. | Administration of yoghurt or Lactobacillus casei to malnourished mice: Comparative effect on lymphoid cells and mucosal reconditioning of the intestine | |
| PERCIVAL | Intestinal health | |
| CN113521112A (en) | Preparation method of vaginal active probiotic liquid for women |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |